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Gastrointestinal stromal tumors (GISTs) have distinct gene expression patterns according to localization, genotype and aggres-
siveness. DNA methylation at CpG dinucleotides is an important mechanism for regulation of gene expression. We performed
targeted DNA methylation analysis of 1.505 CpG loci in 807 cancer-related genes in a cohort of 76 GISTs, combined with
genome-wide mRNA expression analysis in 22 GISTs, to identify signatures associated with clinicopathological parameters
and prognosis. Principal component analysis revealed distinct DNA methylation patterns associated with anatomical localiza-
tion, genotype, mitotic counts and clinical follow-up. Methylation of a single CpG dinucleotide in the non-CpG island promoter
of SPP1 was significantly correlated with shorter disease-free survival. Hypomethylation of this CpG was an independent prog-
nostic parameter in a multivariate analysis compared to anatomical localization, genotype, tumor size and mitotic counts in a
cohort of 141 GISTs with clinical follow-up. The epigenetic regulation of SPP1 was confirmed in vitro, and the functional
impact of SPP1 protein on tumorigenesis-related signaling pathways was demonstrated. In summary, SPP1 promoter methyla-
tion is a novel and independent prognostic parameter in GISTs, and might be helpful in estimating the aggressiveness of
GISTs from the intermediate-risk category.
Gastrointestinal stromal tumors (GISTs) are the most com-
mon mesenchymal tumors of the gastrointestinal tract, most
likely derived from interstitial cells of cajal (ICCs) or their
stem cell precursor cells. The initial events in GIST tumori-
genesis are gain-of-function mutations of the receptor tyro-
sine kinases v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog (KIT) or platelet-derived growth factor
receptor, alpha polypeptide (PDGFRA), occurring in 75 and
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15% of GISTs, respectively.1,2 The histomorphologic appear-
ance and clinical behavior are signiﬁcantly different between
gastric and small intestinal GISTs,3,4 and also between GISTs
with KIT and PDGFRA mutations.5,6 Gastric GISTs and
GISTs with PDGFRA mutations are associated with less
aggressive behavior compared to small intestinal GISTs and
to GISTs with KIT mutations.3–6 Array-based genome-wide
expression studies have shown signiﬁcant differences in
mRNA expression signatures comparing gastric and small
intestinal GISTs,7,8 GISTs with KIT and PDGFRA muta-
tions9,10 and according to risk classiﬁcation.8,11 However, lit-
tle is known about the underlying mechanisms regulating
these expression signatures.
Epigenetic regulation by DNA methylation of cytosine res-
idues in CpG dinucleotides silences gene expression by affect-
ing the recruitment of regulatory proteins to DNA,12 and has
been shown to play causal roles in the pathogenesis of several
cancers.13 However, only limited data have been reported
concerning epigenetic mechanisms in GIST tumorigenesis
and prognosis.14 Two earlier studies have reported downregu-
lation of the CDK inhibitor p16INK4A, partly due to promoter
hypermethylation of the corresponding gene locus CDKN2A,
as a prognostic marker for GIST progression.15,16 Hypome-
thylation of LINE-1 repeats was found to correlate with risk
classiﬁcation and chromosomal instability.17 Another study
has compared the global DNA methylation patterns in GISTs
of different risk categories, and identiﬁed REC8 and PAX3 to
be differentially methylated in small vs. malignant GISTs.18
Epigenetic silencing of the tumor suppressor gene PTEN has
been found after long-term exposure of GIST tumor cells to
sunitinib.19
In our study, we performed targeted DNA methylation
proﬁling in a large cohort of primary GISTs and observed
distinct methylation patterns according to anatomical local-
ization, genotype and mitotic counts. According to the prog-
nostic value of these factors, we established a linear model to
identify DNA methylation events that are associated with
tumor progression independently of the classical clinicopa-
thological parameters mentioned above. On the basis of cor-
relation analysis with gene expression and in vitro ﬁndings,
we demonstrate methylation of Secreted Phosphoprotein 1
(SPP1) promoter as a potent regulator of its expression, and
highlight SPP1 promoter hypomethylation as a novel and
independent prognostic parameter in GISTs.
Material and Methods
Tumor samples
A cohort of 76 fresh-frozen tumor samples from primary
GISTs without previous imatinib treatment was used for tar-
geted DNA methylation analysis (test set). An additional
cohort of 99 parafﬁn-embedded imatinib-na€ıve primary
GISTs was used as the validation set. Clinical follow-up was
available for 42 of the 76 fresh-frozen GISTs of the test set,
and for all 99 parafﬁn-embedded GISTs of the validation set.
For each tumor, DNA was isolated from fresh-frozen or
parafﬁn-embedded tissue using the Qiagen Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s manual,
and DNA concentration was quantiﬁed with a NanoDrop
1000 (Thermo Scientiﬁc, Wilmington, DE). Mutation analysis
of KIT exons 9, 11, 13 and 17 as well as PDGFRA exons 12,
14 and 18 was performed in all 175 samples using the meth-
ods previously described.20 This study was approved by the
ethics committee of the University of G€ottingen (No. 8/9/07).
DNA methylation analysis
The 76 GISTs from the test set were analyzed with the Golden
Gate Methylation Cancer Panel I (Illumina, San Diego, CA) at
1,505 CpG loci associated with 807 cancer-related genes. DNA
methylation patterns of six individual CpG loci in the promoter
region of SPP1 were evaluated by bisulﬁte sequencing in DNA
samples from three GISTs with varying levels of SPP1 methylation
according to the Golden Gate Methylation data set. After sodium
bisulﬁte treatment using the EpiTect bisulﬁte Kit (Qiagen), a
genomic region upstream of the transcription start site of SPP1 was
ampliﬁed by polymerase chain reaction (PCR) using the following
primers: SPP1_SBF1 AATGTGTAAAATTTTTTTATTGATGTA-
TAT and SPP1_SBR1 ATCCTTTACTACTCAAACTTAACTT-
TATAA. PCR products were cloned using the TOPO TA cloning
kit for sequencing (Invitrogen, Carlsbad, CA), and ten individual
clones from each sample were sequenced. Bisulﬁte pyrosequencing
of the most informative SPP1 CpG site (SPP1_P647_F) was per-
formed for all samples. A 73-bp fragment of the SPP1 promoter
region was PCR-ampliﬁed from bisulﬁte-treated DNA (EZ DNA
Methylation-Gold Kit; Zymo Research, Irvine, CA) using
GTATTTTATGGATGAGGGAATAAGGATAG (forward) and
ATCACTACTAACCTATACAACCTTAAAC (reverse) primers.
Pyrosequencing reactions were done using the PyroMark Gold
Q24 Reagents (Qiagen) in a PyroMark Q24 Pyrosequencing Sys-
tem (Qiagen) with the pyrosequencing primer
What’s new?
Variations in the clinical behavior of gastrointestinal stromal tumors (GISTs) are associated with underlying variations in gene
expression. But the mechanisms regulating gene expression in GIST and how they influence tumor progression remain
unclear. A mechanism implicated in the present study is epigenetic dysregulation, specifically of secreted phosphoprotein 1
(SPP1), based on targeted DNA methylation profiling and genome-wide mRNA expression analysis in a cohort of GISTs. In vitro
experiments indicate that SPP1 raises oncogenic potential by influencing the activation of major intracellular regulators. The
findings suggest that SPP1 hypermethylation is an independent prognostic marker in GIST.
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AGGGAATAAGGATAGGTA. Quantiﬁcation of CpG methyla-
tion was performed using the Software PyroMark 24 v.2.0.6 (Qia-
gen), with correction for minor bias toward unmethylated alleles as
previously described.21
mRNA expression analysis
After homogenization of fresh-frozen tumor tissue with an
Ultra Turrax T25 (IKA-Werke GmbH), total RNA was isolated
with TRIzol Reagent (Invitrogen) and total RNA concentration
and integrity was quantiﬁed using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA). Genome-wide mRNA
expression analysis was performed for 22 samples of highest
RNA integrity using the HumanHT-12 v4 Expression Bead-
Chip Kit (Illumina). cDNA synthesis for quantitative RT-PCR
was performed for 51 GISTs of the test set with the Revert-Aid
H Minus First Strand cDNA Synthesis Kit (Fermentas, St.
Leon-Rot, Germany) using 10 ng of total RNA. The qRT-PCRs
for SPP1 and reference genes ACTB and HPRT were performed
with an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems, Weiterstadt, Germany), using probes 61
(for SPP1), 64 (for ACTB) and 73 (for HPRT) of the Universal
Probe Library (Roche, Penzberg, Germany), together with the
following primers: SPP1_forward CGCAGACCTGACATC-
CAGTA, SPP1_reverse GGCTGTCCCAATCAGAAGG;
ACTB_forward CCAACCGCGAGAAGATGA, ACTB_reverse
CCAGAGGCGTACAGGGATAG; HPRT_forward
TGACCTTGATTTATTTTGCATACC, HPRT_reverse
CGAGCAAGACGTTCAGTCCT. Data were analyzed with the
ddCt algorithm (Bioconductor package ddCt).
In vitro inhibition of DNA methylation and SPP1
stimulation in GIST cell lines
Cell culture conditions for GIST cell line GIST882 were as
described previously.22 Cells were cultured for 24 hr and then
treated with 10 or 25 nM concentrations of 5-aza-20-
deoxycytidine (A3656-5MG, Sigma-Aldrich Chemie GmbH,
Munich, Germany) for 72 hr. After treatment, DNA and total
RNA were isolated for DNA methylation analysis using pyro-
sequencing and for mRNA expression analysis using qRT-
PCR as described above. Additionally, protein lysates were
collected, and Western blot analysis of SPP1 protein levels
was performed using a monoclonal anti-SPP1 antibody
(LFMb-14, Santa Cruz Biotechnology, Santa Cruz, CA). To
examine downstream signaling of SPP1, GIST882 cells were
treated with 1 mg recombinant SPP1 after starvation of the
cells, and cell lysis was done on ice at different time points
(0, 5, 15, 30 and 60 min). Western blot analyses for expres-
sion as well as phosphorylation of AKT and ERK1/2 were
carried out as described previously.23
Statistical analysis
Read-outs from Golden Gate Methylation Cancer Panel I
were normalized with logit-transformation. Principal compo-
nents analysis was performed with the ROBPCA algorithm.24
Differential methylation was detected by establishing a linear
model with classical clinical parameters as covariates and by
moderated t-tests followed by Benjamini & Hochberg adjust-
ment to control false-discovery rate (FDR) under 0.01, as
described by the Bioconductor package limma.25 Brieﬂy, for
each CpG locus, the logit-transformed methylation value y
was ﬁtted to the following model:
c  l1bl l1bgg1bmm1bpp;
where m represents the baseline methylation level, l, g, m and
p present factor variables of anatomical localization, geno-
type, mitotic counts and tumor progression, respectively, and
bs represent respective coefﬁcients. By this model, we assume
that the methylation status of each CpG locus can be
explained by the linear combination of four factors. The lin-
ear model was ﬁtted and null hypotheses were tested assum-
ing that the coefﬁcients (bs) equal zero. Benjamini–Hochberg
multiple-testing adjustment was performed. All statistical
tests were performed with R and Bioconductor,26 or with
SPSS Statistics software (IBM, New York, NY).
Results
Unsupervised targeted DNA methylation analysis classifies
GISTs into subgroups correlated to anatomical localization
and genotype
A three-dimensional principal component analysis (PCA)
was performed to detect distinct patterns in 76 fresh-frozen
GIST samples according to the methylation status of 1,505
CpG loci representing 807 cancer-related genes (Fig. 1a).
Correlation with clinicopathological parameters revealed that
the GISTs separated into three distinct groups: gastric with
KIT mutation; small intestine with KIT mutation and gastric
with PDGFRA mutation. Two rectal GISTs with KIT muta-
tion clustered with the gastric KIT-mutated GISTs, while
three wild-type GISTs clustered according to their anatomical
localization (either gastric or small intestinal) among the
KIT-mutated GISTs. Interestingly, one CpG locus located in
the promoter region of the gene prominin 1 (PROM1)/CD133
as well as two CpG loci located in the promoter region of the
gene CD34 molecule (CD34) displayed a similar methylation
pattern, with low methylation levels in KIT-mutated GISTs
from the stomach and rectum, in contrast to high methyla-
tion levels in KIT-mutated GISTs from the small intestine
(Fig. 1 and Table 1).
The methylation status of distinct CpG loci is associated
with anatomical localization, genotype, mitotic counts and
tumor progression in GIST
The standard prognostication of clinical behavior in GIST is
based on the parameters anatomical localization, size and
mitotic counts. Accordingly, novel and additional molecular
parameters have to be of independent prognostic value com-
pared to those well-established and easily accessible factors.
Thus, we used a linear model to identify CpG loci that give
additional prognostic information beyond those classical
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Figure 1. Targeted DNA methylation analysis identified SPP1 as a novel prognostic factor. (a) Unsupervised three-dimensional PCA
reveals distinct patterns of DNA methylation in relation to anatomical localization and genotype. There is a clear separation of three
distinct groups: KIT-mutated GISTs from the stomach (green), KIT-mutated GISTs from the small intestine (blue) and PDGFRA-mutated
GISTs from the stomach (purple). Rectal GISTs (black) cluster with gastric KIT-mutated GISTs, and wild-type GISTs (orange) cluster
according to their anatomical localization within the KIT-mutated tumors. (b) Heatmap of differentially methylated CpG loci according
to clinicopathological parameters and tumor progression. The linear model revealed a significant association of DNA methylation at
specific CpG loci with anatomical localization (25 CpG loci), genotype (three CpG loci), mitotic counts (21 CpG loci) and tumor progres-
sion (two CpG loci). Three CpG loci located in the promoter regions of PROM1/CD133 and CD34 display a similar methylation pattern
within GIST from different sites of the gastrointestinal tract. The linear model further demonstrates that hypomethylation of the CpG
locus SPP1_P647_F in the promoter region of SPP1 is independently correlated to tumor progression. Sm. i.: small intestinal; rec.: rec-
tal; non p.: nonprogressive; p.: progressive; n.a.: not available. (c) Correlation analysis of DNA methylation (y-axis) and genome-wide
mRNA expression (x-axis) was used to detect 31 CpG loci with significant inverse mRNA expression levels of their respective genes
(27), including PROM1/CD133, CD34 and SPP1.
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factors. To achieve this, the linear model calculates for any
CpG locus whether its methylation level is correlated to any of
the parameters, anatomical localization, size and mitotic
counts, and whether a potential prognostic value of its methyl-
ation level is dependent or independent of those parameters.
This linear model was applied to the methylation status of
1,505 CpG loci in 42 fresh-frozen GIST samples from the test
set with clinical follow-up. According to the linear model, 25
CpG loci (22 genes) were associated with anatomical localiza-
tion, three CpG loci (three genes) with genotype and 21 CpG
loci (19 genes) with mitotic counts (Table 1 and Fig. 1b). Fur-
thermore, the linear model revealed that methylation patterns
in the promoter regions of the two genes SPP1 and IFNG were
signiﬁcantly associated with tumor progression, independently
of the clinicopathological parameters described above.
Genome-wide mRNA expression analysis identifies genes
with significant inverse correlation between DNA
methylation and mRNA expression
To determine if GIST-speciﬁc DNA methylation could con-
tribute to distinct gene expression patterns, the levels of
DNA methylation at 1.505 CpG dinucleotides were correlated
to the mRNA expression levels of the respective genes using
genome-wide mRNA expression data for a representative
sample of 22 GIST specimens with highest RNA integrity.
Given a limited number (807) of cancer-related genes that
were interrogated for methylation analyses, this number of
GIST samples sufﬁced for consistent conclusions. Thirty-one
CpG loci corresponding to 27 genes were found to have a
signiﬁcant inverse correlation of DNA methylation and
mRNA expression (Fig. 1c). While PROM1/CD133, CD34
and SPP1 were among those genes with signiﬁcant inverse
correlation, IFNG was not. Bisulﬁte sequencing of a large
portion of the promoter region of SPP1 in three representa-
tive GIST samples with low, intermediate and high SPP1
methylation levels according to the Illumina Golden Gate
Methylation data set revealed strongest regulation of the
non-CpG island CpG dinucleotide located 647 base pairs
upstream of the transcription start site of SPP1 that was also
represented on the array (Figs. 2a and 2d). Pyrosequencing
of this CpG site in all 76 fresh-frozen GIST samples con-
ﬁrmed the initial methylation levels of the Golden Gate
Methylation data set (Fig. 2e; R25 0.94). SPP1 mRNA
expression was further examined by qRT-PCR in 51 of the
76 fresh-frozen GIST samples, revealing a signiﬁcant inverse
correlation between SPP1 DNA methylation determined by
pyrosequencing and SPP1 mRNA expression determined by
qRT-PCR (R2520.50).
SPP1 promoter hypomethylation is an independent
prognosticator for shorter disease-free survival in GISTs
Using univariate Cox proportional hazard models, a signiﬁ-
cant correlation was established between hypomethylation of
the non-island CpG site 647 base pairs upstream of the tran-
scription start site of SPP1 and shorter disease-free survival.
This signiﬁcant correlation was observed both in the initial
test set of fresh-frozen GIST samples with determination of
methylation level using the Illumina Golden Gate method
(p5 0.002), and also in the validation set of parafﬁn-
embedded GIST samples with determination of methylation
levels using pyrosequencing (p5 0.006). Accordingly, univari-
ate and multivariate Cox proportional hazard models com-
paring (i) anatomical localization, (ii) genotype, (iii) tumor
size, (iv) mitotic counts and (v) SPP1 methylation level deter-
mined by pyrosequencing were performed for the whole
cohort of 141 samples with clinical follow-up (Table 2).
Notably, SPP1 methylation level remained as an independent
prognostic parameter in the multivariate analysis (Table 2).
For Kaplan–Meier plot visualization of disease-free survival
according to SPP1 methylation status, the GIST samples were
grouped into three groups with low (<25%), intermediate
(25–75%) and high (>75%) methylation levels of SPP1 (Fig.
3), demonstrating the high correlation of this single methyla-
tion site with disease progression.
On an individual basis, GISTs of the high-risk category
were observed with high SPP1 methylation levels, which
Figure 2. Bisulfite sequencing of the promoter region of SPP1 con-
firmed strongest regulation of CpG at position 647, and pyrose-
quencing validated methylation levels of SPP1 compared to
Illumina Golden Gate data. (a) Overview of the SPP1 promoter
region. The dark gray box on the right and the bent arrow represent
the first exon of SPP1 and the transcription start site, respectively.
The light gray box on the left represents the PCR amplicon used for
bisulfite sequencing, comprising six CpG loci. CpG dinucleotides
are depicted as vertical lines, and the black arrowhead highlights
the CpG site SPP1_P647_F interrogated with the Golden Gate Meth-
ylation Cancer Panel I. (b–d) Bisulfite sequencing of six CpG loci in
three representative GIST samples with high (b), intermediate (c)
and low (d) methylation levels according to the Illumina Golden
Gate data set. Each line represents an individual clone: closed and
open circles represent methylated and unmethylated cytosines,
respectively. (e) SPP1 methylation level comparing pyrosequencing
(y-axis) and Illumina Golden Gate reveals a significant correlation
(R250.935).
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still had a favorable clinical outcome. For example, the
highest methylation level (89.9%) was observed in a GIST
from the small intestine with >10 mitoses/50 HPFs, which
did not progress during a follow-up of 87 months followed
by death of another cause. Regarding the only two GISTs
among the intermediate-risk category that developed tumor
progression, one had lowest methylation levels of only 4%,
and the other one had intermediate methylation levels of
41%. Although only limited conclusion can be drawn from
these individual cases, they support the independent prog-
nostic role of SPP1 methylation levels observed for the
whole study cohort.
SPP1 expression is correlated with its methylation level in
vitro, and has stimulating effects on GIST signaling
pathways
To evaluate whether the observed correlation between SPP1
methylation and expression levels could be reproduced also in
vitro, we treated the GIST cell line GIST882 with different con-
centrations of the demethylating agent 5-aza-20-deoxycytidine
(decitabine) and quantiﬁed the mRNA and protein levels of
SPP1. Decitabine treatment resulted in a decrease in SPP1
methylation accompanied by a dose-dependent increase of
SPP1 mRNA expression after 72 hr of treatment (Figs. 4a and
4b). Protein level of SPP1 was increased with the 10 nM decita-
bine concentration and stayed constant at 25 nM, potentially
indicating saturation at protein level (Figs. 4c and 4d). Further-
more, stimulation of GIST882 cells with 1 mg of recombinant
SPP1 induced phosphorylation of ERK1/2 and, to a lesser
extent, also of AKT, components of major oncogenic pathways
downstream of SPP1 (Fig. 4e). Overall, these in vitro data sup-
port our observations for both SPP1 epigenetic regulation and
oncogenic importance of SPP1 modulation in GIST.
Discussion
We performed a targeted DNA methylation proﬁling analysis
of GISTs, revealing distinct patterns according to anatomical
localization, genotype and mitotic counts. Applying unsuper-
vised machine learning techniques (PCA), GISTs were sepa-
rated into three main subgroups: gastric with KIT mutation,
gastric with PDGFRA mutation and small intestinal with KIT
mutation. Notably, these three GIST subgroups are also char-
acterized by different patterns of mRNA and miRNA expres-
sion,7–11,27 and have distinctive histomorphology and clinical
behavior.3–6 Accordingly, the DNA methylation patterns
identiﬁed in this study likely represent speciﬁc methylation
signatures for these three GIST subgroups, which might
impact the respective mRNA and miRNA expression pat-
terns, as well as their clinical behavior. Notably, only three
genes were differentially methylated in gastric GISTs with
KIT vs. PDGFRA mutations. By contrast, extensive differences
in DNA methylation signatures were demonstrated between
KIT-mutated GISTs in the stomach vs. small intestine, with
differential methylation at 25 CpG loci corresponding to 22
genes. This observation suggests that distinct patterns of epi-
genetic alterations may be involved in GISTs according to
their anatomical origin. Among other genes, the hematopoi-
etic stem cell antigen PROM1/CD133 was hypomethylated in
gastric GISTs, which correlates to its upregulated expres-
sion.28 Interestingly, rectal GISTs with KIT mutation clus-
tered together with KIT-mutated GISTs from the stomach,
consistent with a similar observation based on mRNA expres-
sion proﬁles.7 This close relationship based on epigenetic and
genetic features is in line with the ﬁndings that rectal GISTs
are predominantly of spindle cell type and uniformly coex-
press CD117 and CD34, similar to KIT-mutated gastric
GISTs of the spindle cell type.29 Correspondingly, two CpG
dinucleotides located in the promoter region of CD34 showed
a distinct methylation pattern among GISTs from different
sites of the gastrointestinal tract, with low methylation levels
among KIT-mutated GISTs from the stomach and rectum in
contrast to high methylation levels in KIT-mutated GISTs
from the small intestine. Notably, both PROM1/CD133 and
CD34 were among the genes with a signiﬁcant inverse corre-
lation between DNA methylation and mRNA expression lev-
els in this study. There is accumulating evidence that GISTs
arise from ICCs or their stem cell precursor cells, and it has
Table 2. Univariate and multivariate analyses of clinicopathological
parameters and SPP1 methylation status in the whole cohort of 141
GIST samples
Parameter
Univariate
analysis (p-value)
Multivariate
analysis (p-value)
Anatomical localization 0.02 0.06
Genotype 0.1 0.9
Tumor size 2.5 3 1025 0.003
Mitotic counts 5.5 3 10211 0.00004
SPP1 methylation 6.6 3 1025 0.03
Figure 3. Prognostic impact of SPP1 methylation determined by
pyrosequencing in 141 primary GISTs, comparing tumors with low
(<25%), intermediate (25–75%) and high (>75%) methylation lev-
els (univariate Cox proportional hazards model, p56.6 3 1025).
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been shown that at least four different subpopulations of
ICCs exist, which have a speciﬁc distribution in the gastroin-
testinal tract.30 The distinctive DNA methylation patterns
including CpG sites within the promoter regions of PROM1/
CD133 and CD34 that we report for GISTs from different
sites of the gastrointestinal tract suggest that varying methyl-
ation proﬁles might underlie the gene expression differences
reported for GISTs in these locations, and perhaps reﬂect the
different origins of these GIST subgroups from different
ICC-lineage subpopulations.
To identify novel and independent prognostic markers, a
linear model comparing classical clinicopathological parame-
ters and follow-up was used to identify CpG sites differen-
tially methylated between GISTs with and without
subsequent tumor progression independent of classical prog-
nostic parameters. Additionally, genome-wide mRNA expres-
sion analyses were used to establish CpG loci with signiﬁcant
inverse correlation of DNA methylation and mRNA expres-
sion, focusing on non-CpG island CpG sites with probable
impact on transcription factor binding when compared to
probably more global patterns of DNA methylation deregula-
tion frequently observed during tumor progression. This
focused approach identiﬁed hypomethylation of a CpG dinu-
cleotide 647 base pairs upstream of the transcription start
site of SPP1 to be signiﬁcantly associated with tumor progres-
sion, with inverse correlation to SPP1 mRNA expression.
SPP1 is a chemokine-like, acidic glycoprotein that is secreted
into the extracellular matrix and that binds certain CD44
variants (e.g., CD44v6) and integrin receptors (e.g., avb3).
31
SPP1 binding leads to the activation of major intracellular
signaling regulators, including PI3K/AKT and RAS/MAPK,
thereby effecting the oncogenic potential by promoting prolif-
eration, survival, migration and angiogenesis.32–34 Notewor-
thy, PI3K/AKT and RAS/MAPK are the main activated
signaling pathways in GIST.35,36 Using an in vitro model, we
observed that treatment of GIST882 cells with the demethy-
lating drug decitabine resulted in a dose-dependent downreg-
ulation of SPP1 methylation that was accompanied by an
upregulation of SPP1 mRNA as well as protein, supporting
the relevance of epigenetic regulation on SPP1 expression in
GISTs. Moreover, stimulation of GIST882 cells with SPP1
resulted in the activation of signaling intermediates ERK1/2
and, to a lesser extent, AKT. Altogether, these in vitro ﬁnd-
ings suggest that hypomethylation of SPP1 and the resulting
increase in SPP1 expression may lead to an activation of
downstream signaling components with potential impact on
proliferation and invasion in GISTs. Notably, the independ-
ent prognostic impact of SPP1 methylation levels with respect
to mitotic counts further highlights invasion as a potentially
relevant but yet not well-understood mechanism of tumor
progression in GIST.
SPP1 (osteopontin) has been demonstrated to be a prog-
nostic marker on the protein level in different kinds of can-
cers37–39 and also in GISTs.40,41 Comparing two different
methods and two different GIST cohorts, we established and
Figure 4. SPP1 mRNA and protein expression levels are inversely
correlated to DNA methylation after decitabine treatment in vitro,
and SPP1 activates intracellular signaling cascades in GIST882
cells. (a) SPP1 methylation levels decreased, while SPP1 mRNA
expression (b) and SPP1 protein levels (c, d) increased after treat-
ment of GIST882 cells with increasing doses of DNA methylation
inhibitor (5-aza-20-deoxycytidine or decitabine) for 72 hr. (e) Stimu-
lation of GIST882 cells with 1 mg of recombinant SPP1 resulted in
an increased phosphorylation of ERK1/2 and AKT with different
peaks of activation time.
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validated SPP1 methylation level as an excellent prognostic
factor in GISTs. Using the whole cohort of 141 GISTs with
long-term follow-up, SPP1 methylation level remained an
independent prognostic factor in a multivariate analysis com-
pared to anatomic localization, tumor size and mitotic
counts. Notably, these three parameters are the best predic-
tors of GIST behavior to date, and they are the basis for the
currently used GIST risk classiﬁcations.42,43 Regarding the
independent prognostic value of SPP1 in comparison to these
clinicopathological parameters, we suggest that determination
of SPP1 methylation might be especially valuable in GISTs of
the intermediate-risk categories, for which the clinical behav-
ior is currently unpredictable. In contrast to the already sug-
gested prognostic role of semiquantitative evaluation of SPP1
protein levels,40,41 the analysis of SPP1 methylation degree
has the advantage to be a quantitative parameter, with high-
est sensitivity and reproducibility, and may be easier to
implement into GIST risk classiﬁcations in the future. Given
the fact that DNA analysis by pyrosequencing is now being
routinely performed at many diagnostic molecular pathology
laboratories, quantiﬁcation of SPP1 methylation can be easily
established at different laboratories, which is opposed to
more complex molecular prognostication schemes that
remain restricted to specialized laboratories.44
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